Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
2007 NOV 19 -- A large Phase III clinical trial is anticipated to begin in the second quarter of 2008 to compare the effects of prasugrel, an investigational oral antiplatelet agent, against clopidogrel (Plavix(R)/Iscover(R)) in medically managed patients with acute coronary syndrome (ACS), a group of common heart conditions that includes unstable angina (chest pain) and heart attacks(1). The study, TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes), will include approximately 10,000 patients at more than 800 hospitals in 35 countries. Daiichi Sankyo Company, Limited and Eli Lilly and Company (NYSE:LLY), which are co-developing prasugrel, will conduct the study in conjunction with the Duke Clinical Research Institute (DCRI), the world's largest academic clinical research organization and a part of Duke University Medical Center. Lead study investigator is E. Magnus Ohman, M.D., Professor of Cardiology at Duke University School of Medicine. Keywords: Acute Coronary Syndrome, Antiplatelet, Cardiology, Clinical Trial Research, Clopidogrel, Coronary Artery Disease, Coronary Disease, Fibrinolytic Agent, Heart Attack, Heart Disease, Platelet Aggregation Inhibitor, Unstable Angina, Eli Lilly and Company. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
